GlassScriptPhysician profile
Brandon Liebau
NPI 1902433048
$695.07
in general payments reported to CMS, 2019-2025
18 companies · $464 in 2025
The $464 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $45.30 · 2024: $185 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $649.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $123.42 | 2024-2025 | Auvelity |
| Organon LLC | $66.68 | 2021-2024 | |
| Lilly USA, LLC | $65.35 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $62.91 | 2025 | Breztri, Airsupra |
| Novo Nordisk INC | $60.29 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.28 | 2024-2025 | Jardiance, Ofev |
| Otsuka America Pharmaceutical, INC. | $40.37 | 2024-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $37.21 | 2025 | |
| Pfizer INC. | $35.06 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $32.80 | 2025 | Camzyos |
| Dexcom, INC. | $25.14 | 2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $17.20 | 2025 | Korlym |
| Abbvie INC. | $14.56 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.75 | 2024 | Xifaxan |
| Sumitomo Pharma America, INC. | $13.72 | 2025 | Gemtesa |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $13.67 | 2025 | |
| Merck Sharp & Dohme LLC | $13.55 | 2025 | Capvaxive, Vaxelis, Rotateq |
| Phathom Pharmaceuticals, INC. | $11.11 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Liebau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.